Cetrorelix Acetate Injection

By maintaining consistent inhibition of pituitary LH secretion, it allows follicles to continue developing under gonadotropin support until optimal maturity (typically 18–20 mm in diameter).

In clinical practice, timing of cetrorelix administration is guided by follicular monitoring (ultrasound assessment of follicle size and number combined with hormonal measurements), ensuring synchronized follicular maturation.Human chorionic gonadotropin (hCG) is then administered at the optimal window to trigger ovulation and improve oocyte retrieval rates.

Clinical data show that use of cetrorelix during COS reduces the incidence of premature LH surges to below 5%, significantly lowering the risk of retrieval failure and increasing the proportion of high-quality oocytes by 12%–18% compared with untreated controls. It also improves outcomes in patients with unstable ovarian response or a history of premature LH surges, reducing cycle cancellations due to ovulatory disorders.

Second, it inhibits excessive luteinization of the ovaries, reducing the release of vasoactive substances such as vascular endothelial growth factor, thereby lowering vascular permeability and decreasing ascites and pleural effusion formation.

Clinical studies confirm that antagonist protocols using cetrorelix reduce overall OHSS incidence by 40%–50% and moderate-to-severe OHSS by more than 60% compared with conventional long GnRH agonist protocols. In high responders including PCOS patients, those with prior OHSS, and good ovarian reserve, cetrorelix improves treatment safety, avoids cycle cancellation due to complications, and reduces patient discomfort and medical costs. Its reversibility allows OHSS prevention without compromising subsequent follicular maturation or embryo transfer, achieving both efficacy and safety.

By inhibiting LH secretion, it reduces premature progesterone synthesis and release, delaying endometrial luteinization and aligning endometrial morphology, structure, and molecular markers (e.g., integrins, homeobox genes, leukemia inhibitory factor) with embryonic development. A stable hormonal milieu also reduces abnormal endometrial hyperplasia and vascular dysregulation, promoting normal glandular and stromal development and achieving an optimal implantation thickness of 8–12 mm.

Multicenter clinical studies show that cetrorelix-based antagonist protocols significantly improve endometrial receptivity compared with traditional GnRH agonist regimens, increasing implantation rates by 10%–15% and achieving clinical pregnancy rates above 55%. Benefits are particularly notable in patients with repeated implantation failure or poor endometrial receptivity. Cetrorelix acetate injection has no direct endometrial toxicity, and endometrial function recovers rapidly after cessation, supporting normal progression of subsequent pregnancies and confirming its safety and efficacy in ART.

By suppressing fluctuations in LH levels, it stabilizes luteal function in early pregnancy and reduces the risk of early miscarriage. However, this field remains in the clinical research stage and has not been widely adopted in clinical practice; large-sample, multi-center Treatment of Rare Endocrine Diseases：For rare disorders characterized by abnormal hormone secretion (e.g., idiopathic precocious puberty and diseases related to excessive activation of GnRH receptors), elagolix acetate can block the GnRH signaling pathway, inhibit abnormal hormone secretion, and alleviate disease symptoms. Although relevant research is currently limited, its unique mechanism of action offers potential strategies for the treatment of rare endocrine diseases.